233 related articles for article (PubMed ID: 31118371)
1. A Variation in the ABCC8 Gene Is Associated with Type 2 Diabetes Mellitus and Repaglinide Efficacy in Chinese Type 2 Diabetes Mellitus Patients.
Zhou X; Chen C; Yin D; Zhao F; Bao Z; Zhao Y; Wang X; Li W; Wang T; Jin Y; Lv D; Lu Q; Yin X
Intern Med; 2019 Aug; 58(16):2341-2347. PubMed ID: 31118371
[TBL] [Abstract][Full Text] [Related]
2. PPARD rs2016520 polymorphism affects repaglinide response in Chinese Han patients with type 2 diabetes mellitus.
Song JF; Wang T; Zhu J; Zhou XY; Lu Q; Guo H; Zhang F; Wang Y; Li W; Wang DD; Cui YW; Lv DM; Yin XX
Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):27-32. PubMed ID: 25311380
[TBL] [Abstract][Full Text] [Related]
3. Effects of NOS1AP rs12742393 polymorphism on repaglinide response in Chinese patients with type 2 diabetes mellitus.
Wang T; Wang Y; Lv DM; Song JF; Lu Q; Gao X; Zhang F; Guo H; Li W; Yin XX
Pharmacotherapy; 2014 Feb; 34(2):131-9. PubMed ID: 24338736
[TBL] [Abstract][Full Text] [Related]
4. A variant of GRK5 is associated with the therapeutic efficacy of repaglinide in Chinese Han patients with type 2 diabetes mellitus.
Shang Z; Han F; Zhou X; Bao Z; Zhu J; Wang T; Lu Q; Du L; Li W; Lv D; Yin X
Drug Dev Res; 2018 May; 79(3):129-135. PubMed ID: 29663513
[TBL] [Abstract][Full Text] [Related]
5. IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population.
Huang Q; Yin JY; Dai XP; Pei Q; Dong M; Zhou ZG; Huang X; Yu M; Zhou HH; Liu ZQ
Acta Pharmacol Sin; 2010 Jun; 31(6):709-17. PubMed ID: 20523342
[TBL] [Abstract][Full Text] [Related]
6. NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus.
Sheng FF; Dai XP; Qu J; Lei GH; Lu HB; Wu J; Xu XJ; Pei Q; Dong M; Liu YZ; Zhou HH; Liu ZQ
Clin Exp Pharmacol Physiol; 2011 Aug; 38(8):550-4. PubMed ID: 21631570
[TBL] [Abstract][Full Text] [Related]
7. Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients.
He YY; Zhang R; Shao XY; Hu C; Wang CR; Lu JX; Bao YQ; Jia WP; Xiang KS
Acta Pharmacol Sin; 2008 Aug; 29(8):983-9. PubMed ID: 18664331
[TBL] [Abstract][Full Text] [Related]
8. Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients.
Huang Q; Yin JY; Dai XP; Wu J; Chen X; Deng CS; Yu M; Gong ZC; Zhou HH; Liu ZQ
Eur J Clin Pharmacol; 2010 Dec; 66(12):1207-15. PubMed ID: 20809084
[TBL] [Abstract][Full Text] [Related]
9. NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes.
Gong ZC; Huang Q; Dai XP; Lei GH; Lu HB; Yin JY; Xu XJ; Qu J; Pei Q; Dong M; Zhou BT; Shen J; Zhou G; Zhou HH; Liu ZQ
Br J Clin Pharmacol; 2012 Sep; 74(3):501-9. PubMed ID: 22296034
[TBL] [Abstract][Full Text] [Related]
10. KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients.
Dai XP; Huang Q; Yin JY; Guo Y; Gong ZC; Lei MX; Jiang TJ; Zhou HH; Liu ZQ
Clin Exp Pharmacol Physiol; 2012 May; 39(5):462-8. PubMed ID: 22414228
[TBL] [Abstract][Full Text] [Related]
11. Effect of genetic polymorphism of UCP2-866 G/A on repaglinide response in Chinese patients with type 2 diabetes.
Wang S; Se YM; Liu ZQ; Lei MX; Hao-BoYang ; Sun ZX; Nie SD; Zeng XM; Wu J
Pharmazie; 2012 Jan; 67(1):74-9. PubMed ID: 22393835
[TBL] [Abstract][Full Text] [Related]
12. KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes.
Yu M; Xu XJ; Yin JY; Wu J; Chen X; Gong ZC; Ren HY; Huang Q; Sheng FF; Zhou HH; Liu ZQ
Clin Pharmacol Ther; 2010 Mar; 87(3):330-5. PubMed ID: 20054294
[TBL] [Abstract][Full Text] [Related]
13. A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients.
Zhou X; Zhu J; Bao Z; Shang Z; Wang T; Song J; Sun J; Li W; Adelusi TI; Wang Y; Lv D; Lu Q; Yin X
Sci Rep; 2016 Nov; 6():37293. PubMed ID: 27857189
[TBL] [Abstract][Full Text] [Related]
14. Joint effects of diabetic-related genomic loci on the therapeutic efficacy of oral anti-diabetic drugs in Chinese type 2 diabetes patients.
Chen M; Zhang R; Jiang F; Wang J; Peng D; Yan J; Wang S; Wang T; Bao Y; Hu C; Jia W
Sci Rep; 2016 Mar; 6():23266. PubMed ID: 26983698
[TBL] [Abstract][Full Text] [Related]
15. Association between ABCC8 Ala1369Ser Polymorphism (rs757110 T/G) and Type 2 Diabetes Risk in an Iranian Population: A Case-Control Study.
Bakhtiyari A; Haghani K; Bakhtiyari S; Zaimy MA; Noori-Zadeh A; Gheysarzadeh A; Darabi S; Seidkhani-Nahal A; Amraei M; Alipourfard I
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):441-447. PubMed ID: 32660410
[TBL] [Abstract][Full Text] [Related]
16. Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
He J; Qiu Z; Li N; Yu Y; Lu Y; Han D; Li T; Zhao D; Sun W; Fang F; Zheng J; Fan H; Chen X
Eur J Clin Pharmacol; 2011 Jul; 67(7):701-7. PubMed ID: 21327909
[TBL] [Abstract][Full Text] [Related]
17. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
Johansen OE; Birkeland KI
Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
[TBL] [Abstract][Full Text] [Related]
18. Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus.
Fang FS; Gong YP; Li CL; Li J; Tian H; Huang W; Wang LC; Li L
Eur J Endocrinol; 2014 Jun; 170(6):901-8. PubMed ID: 24694876
[TBL] [Abstract][Full Text] [Related]
19. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
[TBL] [Abstract][Full Text] [Related]
20. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
